AJOVY▼ (FREMANEZUMAB-VFRM) INJECTION


Associated tags: Migraine

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Retrieved on: 
Thursday, April 11, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Fear, Hospital, Safety, Nausea, Teva, TEVA, Doctor of Philosophy, Depression, Migraine, Light, Family, Vomiting, Patient, Aes, Molina Healthcare, Medication, Quality of life, Anxiety, Teva Pharmaceuticals, Sound

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.
  • In the study, AJOVY achieved primary endpoint and all secondary endpoints, significantly reducing the number of migraine days experienced per month, demonstrating superior efficacy over placebo.
  • Study data also show AJOVY was safe and well tolerated with no emerging safety signals.
  • Additional findings from this study are planned for presentation at a medical meeting later this year.